Literature DB >> 15530678

Anti-diphtheria antibody seroprotection rates are similar 10 years after vaccination with dTpa or DTPa using a mathematical model.

Brigitte Cheuvart1, Margaret Burgess, Fred Zepp, Jussi Mertsola, Joanne Wolter, Lode Schuerman.   

Abstract

The reduced antigen content diphtheria, tetanus and pertussis (dTpa) vaccine (Boostrixtrade mark) has been shown to induce a strong booster response to all the vaccine components in 4-6 year olds. However, anti-diphtheria antibody levels were observed to be lower when compared to the "full strength" paediatric DTPa vaccine. To assess the impact of this difference on long-term protection, a mathematical model was developed to predict diphtheria antibody decay over time. The model was based on a linear decrease in log-transformed antibody concentrations after the first year post-vaccination. When applied to data collected 3.5 years after vaccination of 4-6 year olds with either DTPa or dTpa, the model predicted that 10 years post-vaccination, 98.6% of subjects vaccinated with dTpa were likely to remain seroprotected against diphtheria, compared to 99.6% vaccinated with DTPa. Therefore, the difference observed in diphtheria antibody geometric mean concentrations 1 month after booster vaccination at 4-6 years with dTpa or DTPa is unlikely to be of clinical relevance 10 years later at the time of the adolescent booster.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15530678     DOI: 10.1016/j.vaccine.2004.06.012

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Immunogenicity and safety of combined adsorbed low-dose diphtheria, tetanus and inactivated poliovirus vaccine (REVAXIS (®)) versus combined diphtheria, tetanus and inactivated poliovirus vaccine (DT Polio (®)) given as a booster dose at 6 years of age.

Authors:  Vincent Gajdos; Benoit Soubeyrand; Emmanuel Vidor; Patrick Richard; Julie Boyer; Christine Sadorge; Anne Fiquet
Journal:  Hum Vaccin       Date:  2011-05-01

Review 2.  Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2012-09-10       Impact factor: 9.546

3.  Booster vaccination and 1-year follow-up of 4-8-year-old children with a reduced-antigen-content dTpa-IPV vaccine.

Authors:  Roland Sänger; Ulrich Behre; Karl-Heinz Krause; Hans-Peter Loch; Peter Soemantri; Dietmar Herrmann; Eugenie Schmitz-Hauss; Joanne Wolter; Bernard Hoet
Journal:  Eur J Pediatr       Date:  2007-01-18       Impact factor: 3.183

4.  Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccine: a randomized, controlled trial in children primed according to a 2 + 1 schedule in infancy.

Authors:  Giuseppe Ferrera; Mario Cuccia; Gabriele Mereu; Giancarlo Icardi; Gianni Bona; Susanna Esposito; Federico Marchetti; Marc Messier; Sherine Kuriyakose; Karin Hardt
Journal:  Hum Vaccin Immunother       Date:  2012-02-13       Impact factor: 3.452

5.  Booster vaccination: the role of reduced antigen content vaccines as a preschool booster.

Authors:  Giovanni Gabutti; Cecilia Trucchi; Michele Conversano; Giambattista Zivelonghi; Giorgio Zoppi
Journal:  Biomed Res Int       Date:  2014-02-11       Impact factor: 3.411

6.  Use of tetanus-diphtheria (Td) vaccine in children 4-7 years of age: World Health Organization consultation of experts.

Authors:  Shalini Desai; Heather M Scobie; Thomas Cherian; Tracey Goodman
Journal:  Vaccine       Date:  2020-01-23       Impact factor: 3.641

7.  Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation.

Authors:  Chloé Pasin; Irene Balelli; Thierry Van Effelterre; Viki Bockstal; Laura Solforosi; Mélanie Prague; Macaya Douoguih; Rodolphe Thiébaut
Journal:  J Virol       Date:  2019-08-28       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.